Opening an account and how to order EXPAREL

The 133 mg (10 mL) and 266 mg (20 mL) doses of EXPAREL are now available in cartons of 4 and 10 vials. As of March 20, 2017, there are 4 SKUs of EXPAREL available.

NDC #	Dose/vial size	Configuration
65250-266-09	EXPAREL 266 mg/20 mL	Carton of 10 vials
65250-266-04	EXPAREL 266 mg/20 mL	Carton of 4 vials
65250-133-09	EXPAREL 133 mg/10 mL	Carton of 10 vials
65250-133-04	EXPAREL 133 mg/10 mL	Carton of 4 vials

NDC #	65250-266-09
Dose/vial size	EXPAREL 266 mg/20 mL
Configuration	Carton of 10 vials

NDC #	65250-266-04
Dose/vial size	EXPAREL 266 mg/20 mL
Configuration	Carton of 4 vials

NDC #	65250-133-09
Dose/vial size	EXPAREL 133 mg/10 mL
Configuration	Carton of 10 vials

NDC #	65250-133-04
Dose/vial size	EXPAREL 133 mg/10 mL
Configuration	Carton of 4 vials

Order EXPAREL directly from Pacira BioSciences, Inc.

Payment is by credit card only.

Call (855) 803-9480.

In order to bill for EXPAREL using the Healthcare Common Procedure Coding System (HCPCS) code, C9290, the appropriate NDC code must be used.

Click here for more information

For first-time orders

You must have an account with Pacira to make direct orders. If you do not have an account, fill out a Letter of Affiliation.

Fax the form to (855) 803-9481 with

A copy of your facility license
A business card or letterhead displaying the same address

This should be done immediately before calling to place an order.

If you are practicing in the state of Florida, you will also need to fill out and submit the Health Care Clinic Establishment form.

All purchases are subject to Pacira's General Terms & Conditions and Return Goods Policy.

Important Notice

This site is intended to provide medical and product information to health care professionals in the United States.

To report an adverse event, email drugsafety@pacira.com or call 1-855-793-9727.

For medical inquiries related to EXPAREL, submit a request to Medical Information or call 1-855-793-9727.

These are not all of the potential important safety considerations for EXPAREL; please see the full Prescribing Information.

Indication

EXPAREL^® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.
Adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via nerve block were nausea, pyrexia, headache, and constipation.
Adverse reactions with an incidence greater than or equal to 10% following EXPAREL administration via infiltration in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, vision blurred, pruritus, and tachycardia.
Do not admix lidocaine or other non-bupivacaine local anesthetics with EXPAREL. EXPAREL may be administered at least 20 minutes or more following local administration of lidocaine.
EXPAREL is not recommended to be used in the following patient populations: patients <6 years old for infiltration, patients younger than 18 years old for nerve blocks, and/or pregnant patients.
Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.
EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal block, or intravascular or intra-articular use.
The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.
Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability, which may lead to dysrhythmias, sometimes leading to death.
Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.
Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.
Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Please refer to full Prescribing Information.

EXPAREL^® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.

Important Safety Information